Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · page 3 of 50
The slide details a corporate acquisition and concurrent private placement financing.
Deck · other · summarize · overcrowded density
Slide locked Sign in to view
Slide schematic 6/6
image 1/1 paragraph 4/4 title 1/1
Components 6
logo paragraph paragraph paragraph paragraph headline
Tools 2
Audience Definition slide · 70%
Management and BOD: Continuing leadership includes Jonathan D. Alspaugh, President and Chief Financial Officer, and Cortney Caudill, Chief Product Officer, and will be joined by Cameron Turtle, DPhil
Call to action slide · 60%Primary use of proceeds: The proceeds from the private placement are expected to be primarily used to advance the Spyre pipeline and deliver the following anticipated milestones: two INDs for SPY001
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.